Cardiac Amyloidosis
How cardiac amyloidosis is recognised, typed and treated, including ATTR and AL amyloidosis.
Cardiac amyloidosis occurs when abnormal protein deposits accumulate within the heart, causing increased wall thickness, stiffness, conduction disease and heart failure. The two major forms are transthyretin amyloidosis (ATTR) and light-chain amyloidosis (AL); distinguishing them is urgent because treatment differs substantially.
Diagnostic Pathway
Clues may include unexplained heart thickening, heart failure with preserved ejection fraction, low blood pressure, carpal tunnel syndrome, neuropathy or intolerance of standard heart-failure medicines. Blood and urine tests for a monoclonal protein are combined with bone-tracer scintigraphy, echocardiography and cardiac MRI. Tissue biopsy is required in selected or uncertain cases.
Treatment
Congestion is treated carefully, often with diuretics. Disease-modifying therapy depends on the amyloid type: AL amyloidosis requires urgent haematology-led treatment, while selected ATTR patients may benefit from transthyretin-directed therapy. Rhythm, conduction disease, anticoagulation and device decisions need individual assessment.
Family and genetic evaluation may be recommended in hereditary ATTR.
Clinical Depth and Risk Assessment
Risk is not defined by the diagnostic label alone. Symptoms, ECG and rhythm findings, ventricular function, myocardial scar or structural change, family history, associated disease and previous events are integrated. Genetic results, when relevant, require expert interpretation; a variant of uncertain significance is not equivalent to a diagnosis.
Diagnostic Strategy and Limitations
Testing is selected to answer a specific question. ECG, ambulatory monitoring, echocardiography, cardiac MRI, CT, laboratory testing, exercise assessment or invasive evaluation have complementary roles. A normal test may not exclude an intermittent disorder, while an abnormal measurement must be checked against technical quality and clinical probability.
Treatment Decision Framework
Treatment may combine risk-factor control, condition-specific medicines, rhythm or heart-failure therapy, catheter procedures, surgery and implanted devices. These options address different mechanisms and are not automatically substitutes for one another. Expected benefit, uncertainty, procedural burden and the patient’s informed preferences should be discussed explicitly.
Long-Term Follow-up
Follow-up assesses symptoms, exercise capacity, rhythm burden, ventricular function and treatment tolerance over time. Family screening may be appropriate in inherited or suspected inherited disease. New fainting, sustained rapid rhythm, chest pain, neurological symptoms or rapidly worsening breathlessness requires urgent assessment.
Questions to Discuss With the Cardiology Team
- Which finding has the greatest influence on my present risk?
- Which test or treatment would genuinely change management?
- What symptoms should lead to an earlier appointment or emergency care?
- Do relatives need clinical or genetic assessment?
Medical Information Note
This page supports an informed discussion with the clinical team. It does not provide a personal diagnosis, medicine dose or sports-clearance decision.